CN100571750C - 一种治疗荨麻疹的中药汤剂 - Google Patents
一种治疗荨麻疹的中药汤剂 Download PDFInfo
- Publication number
- CN100571750C CN100571750C CNB2007100655060A CN200710065506A CN100571750C CN 100571750 C CN100571750 C CN 100571750C CN B2007100655060 A CNB2007100655060 A CN B2007100655060A CN 200710065506 A CN200710065506 A CN 200710065506A CN 100571750 C CN100571750 C CN 100571750C
- Authority
- CN
- China
- Prior art keywords
- parts
- fructus
- chinese medicine
- treatment
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 54
- 206010046736 Urticarias Diseases 0.000 title claims abstract description 45
- 230000002568 urticarial Effects 0.000 title claims abstract description 12
- 229940079593 drugs Drugs 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 241000628997 Flos Species 0.000 claims description 9
- 241000555712 Forsythia Species 0.000 claims description 7
- 241001180876 Saposhnikovia Species 0.000 claims description 7
- 241001529553 Scoparia <angiosperm> Species 0.000 claims description 7
- 230000000694 effects Effects 0.000 abstract description 22
- 208000003251 Pruritus Diseases 0.000 abstract description 14
- 201000010874 syndrome Diseases 0.000 abstract description 12
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 230000004069 differentiation Effects 0.000 abstract description 3
- 239000010135 fructus aurantii immaturus Substances 0.000 abstract description 3
- 210000004369 Blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 13
- 210000002784 Stomach Anatomy 0.000 description 10
- 239000000796 flavoring agent Substances 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 210000000952 Spleen Anatomy 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 230000001737 promoting Effects 0.000 description 7
- 210000004185 Liver Anatomy 0.000 description 6
- 206010052568 Urticaria chronic Diseases 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 206010007247 Carbuncle Diseases 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 210000004072 Lung Anatomy 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 201000008286 diarrhea Diseases 0.000 description 5
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 201000005404 rubella Diseases 0.000 description 4
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010001928 Amenorrhoea Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000001848 Dysentery Diseases 0.000 description 3
- 208000005679 Eczema Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 231100000614 Poison Toxicity 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 210000003932 Urinary Bladder Anatomy 0.000 description 3
- 230000003187 abdominal Effects 0.000 description 3
- 230000001154 acute Effects 0.000 description 3
- 201000000736 amenorrhea Diseases 0.000 description 3
- 231100000540 amenorrhea Toxicity 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 201000004624 dermatitis Diseases 0.000 description 3
- 231100001003 eczema Toxicity 0.000 description 3
- 201000000297 erysipelas Diseases 0.000 description 3
- 230000003419 expectorant Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000019525 fullness Nutrition 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 210000001015 Abdomen Anatomy 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 208000003455 Anaphylaxis Diseases 0.000 description 2
- 206010002425 Angioedemas Diseases 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010009869 Cold urticaria Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010013990 Dysuria Diseases 0.000 description 2
- 208000001780 Epistaxis Diseases 0.000 description 2
- 241000371997 Eriocheir sinensis Species 0.000 description 2
- 206010016286 Febrile disease Diseases 0.000 description 2
- BJHIKXHVCXFQLS-UYFOZJQFSA-N Fructose Natural products OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 206010019233 Headache Diseases 0.000 description 2
- 208000008454 Hyperhidrosis Diseases 0.000 description 2
- 206010022114 Injury Diseases 0.000 description 2
- 210000003734 Kidney Anatomy 0.000 description 2
- 206010048961 Localised oedema Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 206010072736 Rheumatic disease Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000001139 anti-pruritic Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003908 antipruritic agent Substances 0.000 description 2
- 238000005039 chemical industry Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000000968 intestinal Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000001717 pathogenic Effects 0.000 description 2
- 230000025627 positive regulation of urine volume Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001047 pyretic Effects 0.000 description 2
- 230000000552 rheumatic Effects 0.000 description 2
- 231100000486 side effect Toxicity 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 206010002156 Anal fistula Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000002399 Aphthous Stomatitis Diseases 0.000 description 1
- 208000008624 Aquagenic Urticaria Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 229960004754 Astemizole Drugs 0.000 description 1
- GXDALQBWZGODGZ-UHFFFAOYSA-N Astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 208000002894 Beriberi Diseases 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 229940121657 Clinical Drug Drugs 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 208000006111 Contracture Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 210000003414 Extremities Anatomy 0.000 description 1
- 206010064570 Familial cold autoinflammatory syndrome Diseases 0.000 description 1
- 210000003746 Feathers Anatomy 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N Furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 206010018045 Gastroptosis Diseases 0.000 description 1
- 229940097043 Glucuronic Acid Drugs 0.000 description 1
- 208000001786 Gonorrhea Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 229920002456 HOTAIR Polymers 0.000 description 1
- 206010018830 Haematemesis Diseases 0.000 description 1
- 206010018836 Haematochezia Diseases 0.000 description 1
- 208000006750 Hematuria Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010062060 Hyperlipidaemia Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 210000003026 Hypopharynx Anatomy 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- 208000009481 Laryngeal Edema Diseases 0.000 description 1
- 206010023845 Laryngeal oedema Diseases 0.000 description 1
- 229940067606 Lecithin Drugs 0.000 description 1
- 229960003088 Loratadine Drugs 0.000 description 1
- JCCNYMKQOSZNPW-UHFFFAOYSA-N Loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 1
- 208000004396 Mastitis Diseases 0.000 description 1
- 241001448624 Miliaria Species 0.000 description 1
- 210000004080 Milk Anatomy 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- RJKFOVLPORLFTN-STHVQZNPSA-N Progesterone Natural products O=C(C)[C@@H]1[C@@]2(C)[C@H]([C@H]3[C@@H]([C@]4(C)C(=CC(=O)CC4)CC3)CC2)CC1 RJKFOVLPORLFTN-STHVQZNPSA-N 0.000 description 1
- 208000008425 Protein Deficiency Diseases 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 206010037844 Rash Diseases 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- 206010040400 Serum sickness Diseases 0.000 description 1
- 206010040872 Skin infection Diseases 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- 206010041307 Solar urticaria Diseases 0.000 description 1
- 206010041956 Stasis syndrome Diseases 0.000 description 1
- 210000004243 Sweat Anatomy 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Syngestrets Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 208000006379 Syphilis Diseases 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 206010044008 Tonsillitis Diseases 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 206010068760 Ulcers Diseases 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 206010046740 Urticaria cholinergic Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002605 anti-dotal Effects 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 201000005681 cholinergic urticaria Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 201000009230 common cold Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 230000001882 diuretic Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N levocetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003211 malignant Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000000414 obstructive Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 244000052769 pathogens Species 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 230000000607 poisoning Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 230000003014 reinforcing Effects 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000002522 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-QIUUJYRFSA-N β-D-glucuronic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-QIUUJYRFSA-N 0.000 description 1
Abstract
本发明涉及一种治疗荨麻疹的中药汤剂,它是以土茯苓、茵陈、枳实、地肤子、厚朴和山楂等10多味中草药为原料。具有清肠利湿,祛风止痒的功效。本发明是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而成的。本发明的目的是提供一种治疗荨麻疹的中药汤剂。具有疗效确切、安全方便、无毒副作用、价格低廉的特点。
Description
一种治疗荨麻疹的中药汤剂
絲綱
本发明涉及一种治疗荨麻疹的中药汤剂,是一种治疗荨麻疹以中草药为原 料的中药汤剂。属于中药领域。 背景技术
荨麻疹是由于皮肤、黏膜小血管反应性扩张及渗透性增加而产生的一种局
限性水肿反应。本病较常见,约15%-25%的人一生中至少发生过一次。荨麻疹 中医称为瘾疹、风疹、赤疹、白疹、白游风、风丹等。俗称鬼风疙瘩、风疹块、 风包等。如《证治准绳,风门》中说"夫邪客热在于皮肤,遇风寒所伤则起瘾 疹,热多则色赤,风多则色白,甚者痒痛,搔之则成疮。"又如《外科大成*瘾 疹》"瘾疹者,声小粒魇于皮肤之中,憎寒发热遍身瘙痒。经方:劳汗当风, 乃痤瘫。热微色赤,热甚色黑。由痰热在肺,治宜清肺降痰解表。"
荨麻疹临床表现为大小不等的局限性水肿性风团。风团颜色可呈鲜红色、 淡红色、苍白色或皮肤色,形态可呈圆形、椭圆形、环形或不规则形。风团可 在数分钟内突然发生,可在数分钟到数小时内消失,不留任何痕迹,可此起彼 复,反复发作。其临床特征为迅速发生与消退,退后无痕迹,伴有剧痒。严重 患者可伴有头痛、头晕、关节痛、腹痛、恶心、呕吐、腹泻、胸闷、心慌、声 音嘶哑、呼吸困难,严重者可出现喉头水肿、面色苍白、心率加速、脉搏细弱、 血压下降、意识模糊等过敏性休克,危及生命。临床根据病程长短, 一般把起 病急,病程在三个月以内者称为急性荨麻疹,其发病急骤、风团数目较多,多 伴有全身症状;风团反复发作超过三个月以上者称为慢性荨麻疹,其风团时多 时少,但多数风团较少,全身症状较轻。
荨麻疹常见的病因有:①食物:如鱼、虾、蟹、鸡蛋或牛奶等。②药物: 青霉素、痢特灵、血清、疫苗等。(D感染:扁桃体炎、病毒性肝炎、肠道寄生 虫等。④动物及植物因素:如吸入动物的皮屑、羽毛或花粉等。⑤物理及化学 因素:如冷、热、日光、摩擦及压力等。⑥内脏和全身疾病及情绪紧张均可诱 发本病。
荨麻疹除分为急性荨麻疹和慢性荨麻疹以外还有特殊类型荨麻疹,(l)蛋白 胨性荨麻疹(急性蛋白过敏性荨麻疹)。(2)寒冷性荨麻疹又分为:家族性寒冷 性荨麻疹和获得性寒冷性荨麻疹。(3)热性荨麻疹。(4)胆碱能性荨麻疹。(5)曰光 性荨麻疹。(6)压迫性荨麻疹。(7)水源性荨麻疹。(8)血清病性荨麻疹。(9)自身免
疫性黄体酮性荨麻疹。微血管性水肿(巨大性荨麻疹)。m)人工性荨麻疹。急性荨麻疹经数日或数周消退,原因较易追査,祛除病因后迅速消退。慢性荨 麻疹反复发作,常年不愈。病因复杂难以査明,给患者生活、精神上带来很大 痛苦与不便。当其急性发作时症状严重,可致窒息休克,危及生命。因此,有 关预防减少慢性荨麻疹复发的问题是目前临床治疗方面的难点。
中医治疗急性荨麻疹单用中药治疗即可取得良好的疗效。临床辨证以实 证、热证为主,常见证有风热、血热生风、肠胃湿热等证型,风邪是最主要外
因,治疗以疏风止痒为主;分别配以辛凉解表、清热凉血、清热通腑导滞之药。 慢性荨麻疹中医辨证以虚证、瘀证为多。常见的证型有:脾虚受寒,卫外不固; 气血亏虚;肝肾阴亏,虚风内生;气滞血瘀;冲任失调等。治疗分别以健脾益 气,散寒固表;益气养血,疏风止痒;调补肝肾,养血熄风;活血化瘀,祛风 止痒;调摄冲任为法o
西医认为荨麻疹要预防其复发,首先当发现明确其病因,加以去除。但临 床上往往病因难以发现。故目前西医治疗大多是对症治疗。传统的抗组胺药有 较强的中枢抑制能力易产生嗜睡等副作用,而新一代的抗组胺药如阿司咪唑、 氯雷他定、西替利嗪等一般都不具有嗜睡等副作用,其近期疗效较好,但远期 疗效较差。这对慢性荨麻疹的治疗及减少其复发率来说,疗效往往不够理想。 发明内容
本发明是在传统的中医辨证治疗的基础上结合现代最新科研成果研制而 成的。本发明的目的是提供一种治疗荨麻疹的中药汤剂。具有疗效确切、安全 方便、无毒副作用、价格低廉的特点。
本发明是由下述重量配比的原料制成的:
土茯苓1. 5〜6份 茵陈1. 5〜6份 连翘1. 0〜4份 紫苏叶1. 5〜6份 枳实1. 0〜4份 赤芍1. 0〜4份 金银花1.0〜4份 厚朴1.0〜4份 防风L0〜4份 地肤子0.1〜2份 大黄O. 1〜2份 山楂0.1〜2份 本发明的优选配方各原料的重量配比是:
土茯苓2.5〜3.5份 茵陈2.5〜3.5份 连翘1. 5〜2. 5份 紫苏叶2.5〜3.5份 枳实1,5〜2.5份 赤芍1. 5〜2. 5份 金银花1.5〜2.5份 厚朴1.5〜2.5份 防风1.5〜2.5份 地肤子0.5〜1.5份 大黄0.5〜1.5份 山楂0.5〜1.5份 本发明的最佳配方各原料的重量配比是:
土茯苓3份 茵陈3份 连翘2份
紫苏叶3份 枳实2份 赤芍2份
金银花2份 厚朴2份 防风2份地肤子1份 大黄1份 山楂1份
本发明中的药物机理如下:
土茯苓性味甘、淡、平。归肝、胃经。具有清热解毒,祛风湿,强筋骨, 利关节,抗癌的功效。可治疗湿热疮毒,湿疹,风湿骨痛,肢体拘挛,杨梅恶 疮,泌尿系统感染,梅毒,淋浊,淋症白带,消化不良,腹湾,脚气,疔搭, 痈肿,瘰疬等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社
1999年版第87页)。
茵陈药性微苦、微辛,微寒。归脾、胃、膀胱经。具有清热利湿,退 黄的功效。可治疗黄疽,小便不利,湿疮瘙痒等。(《中药大辞典》南京中医 药大学编著上海科学技术出版社第二版第2146页)。
连翘性味苦、微寒。归肺、心、小肠经。具有清热解毒,消结散肿,清 心利尿的功效。可治疗痈疽、瘰疬、乳痈、丹毒、风热感冒、温病初起、温热 入营、高热烦渴、神昏发斑,热淋尿闭等。(季宇彬主编《抗癌中药药理与应 用》黑龙江科学技术出版社1999年版第669页)。
紫苏叶药性辛,温。归肺、脾、胃经。具有散寒解表,行气化痰,安 胎,解鱼蟹毒。可治疗风寒表症,晐嗽痰多,胸脘胀满,恶心呕吐,腹痛吐泻, 胎气不和,妊娠恶阻,食鱼蟹中毒等。(《中药大辞典》南京中医药大学编 著上海科学技术出版社第二版第3288页)。
枳实药性苦、辛,微寒。归脾、胃、大肠经。具有破气消积,化痰除 痞的功效。可治疗积滞内停,痞满胀痛,大便秘结,泻痢后重,结胸,胸痹, 胃下垂,子宫脱垂,脱肛等。(《中药大辞典》南京中医药大学编著上海科 学技术出版社第二版第2230页)。
赤芍性味辛、苦、味寒。归肝经。具有清热凉血,散瘀止痛的功效。可
治疗温毒发斑,吐血衄血,目赤肿痛,肝郁胁痛,经闭痛经,症瘕腹痛,跌打 损伤,痈肿疮疡等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出 版社1999年版第659页)。
金银花性味甘、寒。归肺、心、胃经。具有清热解毒,凉散风热的功效。 可治疗痈肿疔疮,瘰疬,痔漏,喉痹,丹毒,热毒血痢,风热感冒,温病发热 等。(季宇彬主编《抗癌中药药理与应用》黑龙江科学技术出版社1999年版第 830页〉。
厚朴药性苦、辛,温。归胃、大肠经。具有行气导滞,燥湿,降逆平喘 的功效。可治疗食积气滞,腹胀便秘,湿阻中焦,脘痞吐泻,痰壅气逆,胸满 喘晐等。(《中药大辞典》南京中医药大学编著上海科学技术出版社第二版 第2284页)。防风性味辛、甘,温。归膀胱、肝、脾经。具有解表祛风,胜湿,止痉 的功效。可治疗感冒头痛,风湿痹痛,风疹瘙痒,破伤风等。(国家药典委员
会编《中华人民共和国药典》2000年版一部第117页化学工业出版社)。
地肤子性味辛、苦,寒。归肾、膀胱经。具有清热利湿,祛风止痒的功 效。可治疗小便湿痛,阴痒带下,风疹,湿疹,皮肤瘙痒等。(国家药典委员 会编《中华人民共和国药典》2000年版一部第93页化学工业出版社)。
大黄药性苦,寒。归胃、大肠、肝、脾经。具有攻积滞,清湿热,泻 火,凉血,祛瘀,解毒的功效。可治疗食积便秘,热结胸痞;湿热泻痢,黄疸, 淋病,水肿腹满,小便不利;目赤,咽喉肿痛,口舌生疮,胃热呕吐;吐血, 咯血,衄血,便血,尿血;蓄血,经闭,产后瘀滞腹痛,癥瘕积聚,跌打损伤; 热毒痈疡,丹毒,烫伤等。(《中药大辞典》南京中医药大学编著上海科 学技术出版社第二版第141页)。
山楂药性酸、甘,微温。归脾、胃、肝经。具有消食健胃,行气散瘀 的功效。可治疗饮食积滞,脘腹胀痛,泻泄痢疾、经闭,产后腹痛,恶露不尽, 疝气或睾丸肿痛,高血脂症等。(《中药大辞典》南京中医药大学编著上海 科学技术出版社第二版第226页)。
本发明遵循中医"君臣佐使"的组方原则,用土茯茶、茵陈和紫苏叶为君 药;用金银花、枳实、防风、厚朴、连翘和赤芍为臣药;用地肤子、大黄和Llj — 楂为佐使药。诸药相合,共具清肠利湿,祛风止痒的功效。治疗荨麻疹具有疗 效确切,无毒副作用,服用方便,价格低廉的特点。
本发明药物临床使用结果表明,有如下优点-
1、 本发明选用的中草药各组份符合中华人民共和国药品管理法的规定,利 用各味中药的综合作用治疗荨麻疹,对人体无毒无害。经动物急性毒性实验表 明被实验的动物未见任何毒性反应,其主要脏器也无明显的改变,药物安全可 靠。 ;
2、 本发明无须煎煮,无苦涩感,药中富含蛋白质,葡萄糖,葡萄糖醛酸,挥发 油,果胶,果糖,有机酸,卵磷脂,维生素,氨基酸,还含皂甙,植物甾醇和钙等多 种微量元素,利于人体吸收,增强体质。
3、 本发明不仅可有效的治疗荨麻疹,对荨麻疹的预防也有很好的作用,治 疗荨麻疹具有疗效确切,无毒副作用,服用方便,价格低廉的特点。
下面通过临床应用例进一步说明本发明药物对治疗荨麻疹的治疗效果。 荨麻疹疗效判定标准:①治愈:风团消退,临床体征消失,不再发作者。②好 转:风团消退30%或消退后复发间隔时间延长,瘙痒等症状减轻者。③未愈:风
团及瘙痒无明显改善者,或消退不足30%。(戴慎等主编《中医病证诊疗标准:与方剂选用》人民卫生出版社2001年版第859页)。
为表明本发明药物对治疗荨麻疹的治疗效果,经临床试验结果如下;治疗 荨麻疹患者44例,男性25例,女性19例,年龄为18〜56岁。服用实施例汤剂,每 次1袋, 一日二至三次,饭前半小时服用。 一个月为一个疗程,连续服用三个疗 程观察疗效。痊愈34例占77%,好转7例占16%,未愈3例占7%,总有效率达93 %。经三个疗程治疗后,患者风团和瘙痒等症状均有明显改善或痊愈。且病人无 任何不良反应,三大常规化验及肝肾功能检测未发现异常。 具体实施方式
实施例 汤剂按下述重量称取原料:
土茯苓3份 茵陈3份 连翘2份
紫苏叶3份 枳实2份 赤芍2份
金银花2份 厚朴2份 防风2份
地肤子1份 大黄1份 山楂1份
制备方法是取上述原料洗净去杂,晾干,粉碎成颗粒,加水浸泡l小时, 置多功能提取罐中加水煎煮二次,第一次加总药材10倍量的水,煎煮1.5〜2小 时,取煎液,滤过。第二次加总药材7倍量的水,煎煮1〜1.2小时,取两次煎 液,滤过,热封袋中,105'C高温灭菌,包装即得。本发明制成的荨麻疹汤剂 塑封袋装,每袋210ml, 口服, 一次一袋,每日二至三次。 一个月为一个疗程。
Claims (3)
1、一种治疗荨麻疹的中药汤剂,其特征在于它是由下述重量配比的原料药制成的: 土茯苓1.5~6份 茵陈1.5~6份 连翘1.0~4份 紫苏叶1.5~6份 枳实1.0~4份 赤芍1.0~4份 金银花1.0~4份 厚朴1.0~4份 防风1.0~4份 地肤子0.1~2份 大黄0.1~2份 山楂0.1~2份。
2、 根据权利要求1所述的一种治疗荨麻疹的中药汤剂,其中各原料药的重i 配比是:茵陈2,5〜3. 5份 枳实1.5〜2.5份 厚朴1.5〜2.5份 大黄O. 5〜1.5份
3、 根据权利要求1所述的一种治疗荨麻疹的中药汤剂,其中各原料药的重量 配比是:土茯苳2.5〜3.5份 紫苏叶2. 5〜3.5份 金银花1.5〜2. 5份 地肤子0. 5〜1.5份连翘1.5〜2.5份 赤芍1. 5〜2. 5份 防风1. 5〜2. 5份 山楂O. 5〜1.5份《土茯苓3份 紫苏叶3份 金银花2份 地肤子l份茵陈3份 枳实2份 厚朴2份 大黄l份连翘2份 赤芍2份 防风2份 山楂l份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100655060A CN100571750C (zh) | 2007-04-16 | 2007-04-16 | 一种治疗荨麻疹的中药汤剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2007100655060A CN100571750C (zh) | 2007-04-16 | 2007-04-16 | 一种治疗荨麻疹的中药汤剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101028422A CN101028422A (zh) | 2007-09-05 |
CN100571750C true CN100571750C (zh) | 2009-12-23 |
Family
ID=38714079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2007100655060A Expired - Fee Related CN100571750C (zh) | 2007-04-16 | 2007-04-16 | 一种治疗荨麻疹的中药汤剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100571750C (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101569728B (zh) * | 2008-05-04 | 2012-04-25 | 黄艺华 | 一种治疗荨麻疹的药物组合物 |
-
2007
- 2007-04-16 CN CNB2007100655060A patent/CN100571750C/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
荨麻疹的中医治疗概况. 肖红丽.中国中医药信息杂志,第6卷第6期. 1999 |
荨麻疹的中医治疗概况. 肖红丽.中国中医药信息杂志,第6卷第6期. 1999 * |
Also Published As
Publication number | Publication date |
---|---|
CN101028422A (zh) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100415280C (zh) | 一种治疗荨麻疹的中药制剂 | |
CN101129723A (zh) | 治疗便秘的一种中药制剂 | |
CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
CN101095780A (zh) | 治疗糖尿病性脂肪肝的中药制剂 | |
CN101085314A (zh) | 一种治疗月经后期的中成药 | |
CN101028372B (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN101249151A (zh) | 一种治疗风湿痹的中药制剂 | |
CN101085339A (zh) | 一种治疗慢性肾炎的中药组合 | |
CN100571750C (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN100571732C (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN102973711A (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN101085281A (zh) | 治疗慢性肾炎的一种中药 | |
CN100571744C (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN101116711A (zh) | 一种治疗产后小便失禁的中药组合物 | |
CN101085259A (zh) | 治疗慢性肾炎的中药汤剂 | |
CN101028427B (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN101028426A (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN102406913A (zh) | 一种治疗郁证的中药组合物 | |
CN105999060A (zh) | 一种治疗妇女血瘀型癥瘕的中药组合物及其制备方法 | |
CN105663657A (zh) | 一种可有效治疗阴虚火旺的汤剂药物及其制备方法 | |
CN105456617A (zh) | 一种治疗肝郁化火证的内服中药丸及其制备方法 | |
CN101129881A (zh) | 一种治疗乳房带状疱疹的中药组合物 | |
CN101095919A (zh) | 一种治疗糖尿病性胆结石的中成药 | |
CN100571765C (zh) | 一种治疗荨麻疹的中药汤剂 | |
CN104940777A (zh) | 一种治疗肝旺脾弱型经行泄泻的冲剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20091223 Termination date: 20100416 |